Hearing loss in children treated for multidrug-resistant tuberculosis

Journal of Infection

Volumn 66, Issue 4, 2013, Pages 320-329

  Seddon, James A ^a,b   Thee, Stephanie ^c   Jacobs, Kayleen ^d   Ebrahim, Adam ^d   Hesseling, Anneke C ^a   Schaaf, H Simon ^a,e  

^a UNIVERSITY OF STELLENBOSCH   (South Africa)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d Brooklyn Chest Hospital   (South Africa)

^e STELLENBOSCH UNIVERSITY   (South Africa)

Author keywords

Audiology; Children; Hearing; Multidrug resistant; Ototoxicity; Paediatric; Resistant; Tuberculosis

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIRETROVIRUS AGENT; CAPREOMYCIN; KANAMYCIN; POLYPEPTIDE ANTIBIOTIC AGENT; STREPTOMYCIN;

ADOLESCENT; ANTIBIOTIC SENSITIVITY; ARTICLE; AUDIOMETRY; CHILD; CONTROLLED STUDY; DISEASE CLASSIFICATION; DISEASE COURSE; FEMALE; HEARING AID; HEARING IMPAIRMENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; INFECTION RISK; LIQUID CULTURE; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANT TUBERCULOSIS; OTOACOUSTIC EMISSION; PRESCHOOL CHILD; RETROSPECTIVE STUDY; RISK FACTOR; SCHOOL CHILD; SOUTH AFRICA; TREATMENT DURATION;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTITUBERCULAR AGENTS; AUDIOMETRY; CHILD; CHILD, PRESCHOOL; FEMALE; HEARING LOSS; HIV INFECTIONS; HUMANS; INFANT; MALE; MYCOBACTERIUM TUBERCULOSIS; OTOACOUSTIC EMISSIONS, SPONTANEOUS; SOUTH AFRICA; TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY;

EID: 84875520720     PISSN: 01634453     EISSN: 15322742     Source Type: Journal    
DOI: 10.1016/j.jinf.2012.09.002     Document Type: Article

References (52)

1. World Health Organization, Geneva, Switzerland Global tuberculosis control 2011, WHO/HTM/TB/201116.
2. World Health Organization, Geneva, Switzerland Guidlelines for the programmatic management of drug-resistant tuberculosis - emergency update 2008, WHO/HTM/TB/2008402.
3. van Rie A., Beyers N., Gie R.P., Kunneke M., Zietsman L., Donald P.R. Childhood tuberculosis in an urban population in South Africa: burden and risk factor. Arch Dis Child 1999, 80(5):433-437.
4. Marais B.J., Hesseling A.C., Gie R.P., Schaaf H.S., Beyers N. The burden of childhood tuberculosis and the accuracy of community-based surveillance data. Int J Tuberc Lung Dis 2006, 10(3):259-263.
5. World Health Organization, Geneva, Switzerland Automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB/RIF system. Policy statement Available at:, [accessed August 2012]. http://whqlibdoc.who.int/publications/2011/9789241501545_eng.pdf.
6. World Health Organization, Geneva, Switzerland Molecular line probe assays for the rapid screening of patients at risk of multidrug-resistant tuberculosis (MDR-TB). Policy statement Available at:, [accessed August 2012]. http://www.who.int/tb/features_archive/policy_statement.pdf.
7. Seddon J.A., Hesseling A.C., Willemse M., Donald P.R., Schaaf H.S. Culture-confirmed multidrug-resistant tuberculosis in children: clinical features, treatment, and outcome. Clin Infect Dis 2012, 54(2):157-166.
8. Drobac P.C., Mukherjee J.S., Joseph J.K., Mitnick C., Furin J.J., del Castillo H., et al. Community-based therapy for children with multidrug-resistant tuberculosis. Pediatrics 2006, 117(6):2022-2029.
9. Ettehad D., Schaaf H.S., Seddon J.A., Cooke G.S., Ford N. Treatment outcomes for children with multidrug-resistant tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis 2012, 12(6):449-456.
10. Nicol M.P., Workman L., Isaacs W., Munro J., Black F., Eley B., et al. Accuracy of the Xpert MTB/RIF test for the diagnosis of pulmonary tuberculosis in children admitted to hospital in Cape Town, South Africa: a descriptive study. Lancet Infect Dis 2011, 11(11):819-824.
11. Hazbon M.H., Brimacombe M., Bobadilla del Valle M., Cavatore M., Guerrero M.I., Varma-Basil M., et al. Population genetics study of isoniazid resistance mutations and evolution of multidrug-resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother 2006, 50(8):2640-2649.
12. Handbook of anti-tuberculosis agents. Tuberculosis (Edinb) 2008, 88(2):1-169.
13. McCracken G.H. Aminoglycoside toxicity in infants and children. Am J Med 1986, 80(6B):172-178.
14. Mingeot-Leclercq M.P., Tulkens P.M. Aminoglycosides: nephrotoxicity. Antimicrob Agents Chemother 1999, 43(5):1003-1012.
15. Guthrie O.W. Aminoglycoside induced ototoxicity. Toxicology 2008, 249(2-3):91-96.
16. Selimoglu E. Aminoglycoside-induced ototoxicity. Curr Pharm Des 2007, 13(1):119-126.
17. Moeller M.P. Current state of knowledge: psychosocial development in children with hearing impairment. Ear Hear 2007, 28(6):729-739.
18. Moeller M.P., Tomblin J.B., Yoshinaga-Itano C., Connor C.M., Jerger S. Current state of knowledge: language and literacy of children with hearing impairment. Ear Hear 2007, 28(6):740-753.
19. Livingstone N., McPhillips M. Motor skill deficits in children with partial hearing. Dev Med Child Neurol 2011, 53(9):836-842.
20. American Speech-Language-Hearing Association Guidelines for audiologic screening (Guideline) Available at:, [accessed August 2012]. http://www.asha.org/docs/pdf/GL1997-00199.pdf.
21. Schaaf H.S., Marais B.J., Hesseling A.C., Brittle W., Donald P.R. Surveillance of antituberculosis drug resistance among children from the Western Cape Province of South Africa-an upward trend. Am J Public Health 2009, 99(8):1486-1490.
22. American Speech-Language-Hearing Association Guidelines for the audiologic assessment of children from birth to 5 years of age Available at:, [accessed August 2012]. http://www.asha.org/docs/pdf/GL2004-00002.pdf.
23. Dhooge I., Dhooge C., Geukens S., De Clerck B., De Vel E., Vinck B.M. Distortion product otoacoustic emissions: an objective technique for the screening of hearing loss in children treated with platin derivatives. Int J Audiol 2006, 45(6):337-343.
24. Beahan N., Reichman E., Kei J., Driscoll C., Young J., Suppiah R., et al. DPOAE changes in young children with confirmed hearing loss due to ototoxicity. Aust N Z J Audiol 2006, 28(2):90-105.
25. Prayle A., Watson A., Fortnum H., Smyth A. Side effects of aminoglycosides on the kidney, ear and balance in cystic fibrosis. Thorax 2010, 65(7):654-658.
26. Seddon J.A., Godfrey-Faussett P., Jacobs K., Ebrahim A., Hesseling A.C., Schaaf H.S. Hearing loss in patients on treatment for drug-resistant tuberculosis. Eur Respir J Jun 27 2012, [Epub ahead of print].
27. South African health review 2010. Health and related indicators. Available at: [accessed 17.04.12]. http://www.hst.org.za/sites/default/files/sahr10_21.pdf.
28. Seddon J.A., Hesseling A.C., Marais B.J., Jordaan A., Victor T., Schaaf H.S. The evolving epidemic of drug-resistant tuberculosis among children in Cape Town, South Africa. Int J Tuberc Lung Dis 2012, 16(7):928-933.
29. Carhart R., Jerger J.F. Preferred methods for clinical determination of pure-tone thresholds. J Speech Hear Res 1959, 24:330-345.
30. Goodman A. Reference zero levels for pure tone audiometer. ASHA 1965, 7:262-263.
31. Katz J., Medwetsky L., Burkard R., Hood L.J. Handbook of clinical audiology 2009, Lippincott Williams & Wilkins. 6th ed.
32. American Speech-Language-Hearing Association. Audiologic screening (Technical report). 1994;Available at: [accessed August 2012]. http://www.asha.org/docs/pdf/TR1994-00238.pdf.
33. American Speech-Language-Hearing Association Audiologic management of individuals receiving cochleotoxic drug therapy (Guideline) Available from:, [accessed August 2012]. http://www.asha.org/docs/pdf/GL1994-00003.pdf.
34. de Jager P., van Altena R. Hearing loss and nephrotoxicity in long-term aminoglycoside treatment in patients with tuberculosis. Int J Tuberc Lung Dis 2002, 6(7):622-627.
35. Peloquin C.A., Berning S.E., Nitta A.T., Simone P.M., Goble M., Huitt G.A., et al. Aminoglycoside toxicity: daily versus thrice-weekly dosing for treatment of mycobacterial diseases. Clin Infect Dis 2004, 38(11):1538-1544.
36. Sturdy A., Goodman A., Jose R.J., Loyse A., O'Donoghue M., Kon O.M., et al. Multidrug-resistant tuberculosis (MDR-TB) treatment in the UK: a study of injectable use and toxicity in practice. J Antimicrob Chemother 2011, 66(8):1815-1820.
37. Satti H., McLaughlin M.M., Omotayo D.B., Keshavjee S., Becerra M.C., Mukherjee J.S., et al. Outcomes of comprehensive care for children empirically treated for multidrug-resistant tuberculosis in a setting of high HIV prevalence. PLoS One 2012, 7(5):e37114.
38. Rao S.C., Ahmed M., Hagan R. One dose per day compared to multiple doses per day of gentamicin for treatment of suspected or proven sepsis in neonates. Cochrane Database Syst Rev 2006, (1):CD005091.
39. Smyth A.R., Bhatt J. Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis. Cochrane Database Syst Rev 2010, (1):CD002009.
40. Deutsch E.S., Bartling V., Lawenda B., Schwegler J., Falkenstein K., Dunn S. Sensorineural hearing loss in children after liver transplantation. Arch Otolaryngol Head Neck Surg 1998, 124(5):529-533.
41. Bess F.H., Dodd-Murphy J., Parker R.A. Children with minimal sensorineural hearing loss: prevalence, educational performance, and functional status. Ear Hear 1998, 19(5):339-354.
42. Eisenberg L.S. Current state of knowledge: speech recognition and production in children with hearing impairment. Ear Hear 2007, 28(6):766-772.
43. Jerger S. Current state of knowledge: perceptual processing by children with hearing impairment. Ear Hear 2007, 28(6):754-765.
44. Stelmachowicz P.G., Pittman A.L., Hoover B.M., Lewis D.E., Moeller M.P. The importance of high-frequency audibility in the speech and language development of children with hearing loss. Arch Otolaryngol Head Neck Surg 2004, 130(5):556-562.
45. Yoshinaga-Itano C., Sedey A.L., Coulter D.K., Mehl A.L. Language of early- and later-identified children with hearing loss. Pediatrics 1998, 102(5):1161-1171.
46. Moeller M.P. Early intervention and language development in children who are deaf and hard of hearing. Pediatrics 2000, 106(3):E43.
47. Bardien S., de Jong G., Schaaf H.S., Harris T., Fagan J., Petersen L. Aminoglycoside-induced hearing loss: South Africans at risk. S Afr Med J 2009, 99(6):440-441.
48. Bardien S., Human H., Harris T., Hefke G., Veikondis R., Schaaf H.S., et al. A rapid method for detection of five known mutations associated with aminoglycoside-induced deafness. BMC Med Genet 2009, 10:2.
49. Cortopassi G., Hutchin T. A molecular and cellular hypothesis for aminoglycoside-induced deafness. Hear Res 1994, 78(1):27-30.
50. Hutchin T., Haworth I., Higashi K., Fischel-Ghodsian N., Stoneking M., Saha N., et al. A molecular basis for human hypersensitivity to aminoglycoside antibiotics. Nucleic Acids Res 1993, 21(18):4174-4179.
51. Sha S.H., Qiu J.H., Schacht J. Aspirin to prevent gentamicin-induced hearing loss. N Engl J Med 2006, 354(17):1856-1857.
52. Kalinec G.M., Fernandez-Zapico M.E., Urrutia R., Esteban-Cruciani N., Chen S., Kalinec F. Pivotal role of Harakiri in the induction and prevention of gentamicin-induced hearing loss. Proc Natl Acad Sci U S A 2005, 102(44):16019-16024.